首页 > 最新文献

BMJ Surgery Interventions Health Technologies最新文献

英文 中文
Computer-assisted simulated workplace-based assessment in surgery: application of the universal framework of intraoperative performance within a mixed-reality simulation. 计算机辅助的基于工作场所的手术评估:混合现实模拟中术中表现通用框架的应用
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000135
Philipp Stefan, Michael Pfandler, Aljoscha Kullmann, Ulrich Eck, Amelie Koch, Christoph Mehren, Anna von der Heide, Simon Weidert, Julian Fürmetz, Ekkehard Euler, Marc Lazarovici, Nassir Navab, Matthias Weigl

Objectives: Workplace-based assessment (WBA) is a key requirement of competency-based medical education in postgraduate surgical education. Although simulated workplace-based assessment (SWBA) has been proposed to complement WBA, it is insufficiently adopted in surgical education. In particular, approaches to criterion-referenced and automated assessment of intraoperative surgical competency in contextualized SWBA settings are missing.Main objectives were (1) application of the universal framework of intraoperative performance and exemplary adaptation to spine surgery (vertebroplasty); (2) development of computer-assisted assessment based on criterion-referenced metrics; and (3) implementation in contextualized, team-based operating room (OR) simulation, and evaluation of validity.

Design: Multistage development and assessment study: (1) expert-based definition of performance indicators based on framework's performance domains; (2) development of respective assessment metrics based on preoperative planning and intraoperative performance data; (3) implementation in mixed-reality OR simulation and assessment of surgeons operating in a confederate team. Statistical analyses included internal consistency and interdomain associations, correlations with experience, and technical and non-technical performances.

Setting: Surgical simulation center. Full surgical team set-up within mixed-reality OR simulation.

Participants: Eleven surgeons were recruited from two teaching hospitals. Eligibility criteria included surgical specialists in orthopedic, trauma, or neurosurgery with prior VP or kyphoplasty experience.

Main outcome measures: Computer-assisted assessment of surgeons' intraoperative performance.

Results: Performance scores were associated with surgeons' experience, observational assessment (Objective Structured Assessment of Technical Skill) scores and overall pass/fail ratings. Results provide strong evidence for validity of our computer-assisted SWBA approach. Diverse indicators of surgeons' technical and non-technical performances could be quantified and captured.

Conclusions: This study is the first to investigate computer-assisted assessment based on a competency framework in authentic, contextualized team-based OR simulation. Our approach discriminates surgical competency across the domains of intraoperative performance. It advances previous automated assessment based on the use of current surgical simulators in decontextualized settings. Our findings inform future use of computer-assisted multidomain competency assessments of surgeons using SWBA approaches.

目的:基于工作场所的评估(WBA)是基于能力的医学教育在研究生外科教育中的关键要求。虽然基于工作场所的模拟评估(SWBA)已被提议作为WBA的补充,但它在外科教育中的应用还不够。特别是,在情境化的SWBA环境中,缺乏标准参考和自动评估术中手术能力的方法。主要目标是(1)应用术中表现的通用框架和脊柱手术(椎体成形术)的示范性适应;(2)开发基于标准参考度量的计算机辅助评估;(3)情境化、团队化手术室(OR)模拟的实施及有效性评估。设计:多阶段开发与评估研究:(1)基于框架绩效域的绩效指标专家定义;(2)根据术前计划和术中表现数据制定相应的评估指标;(3)在联盟团队中实施混合现实手术室模拟和评估外科医生。统计分析包括内部一致性和领域间的关联,与经验的相关性,以及技术和非技术性能。地点:手术模拟中心。在混合现实手术室模拟中建立完整的外科团队。参与者:从两所教学医院招募了11名外科医生。入选标准包括骨科、外伤或神经外科专家,既往有VP或后凸成形术经验。主要观察指标:计算机辅助评估外科医生术中表现。结果:表现评分与外科医生的经验、观察性评估(客观结构化技术技能评估)评分和总体合格/不合格评分相关。结果为我们的计算机辅助SWBA方法的有效性提供了强有力的证据。外科医生的技术和非技术表现的各种指标可以量化和捕获。结论:本研究首次在真实情境化团队手术室模拟中研究基于胜任力框架的计算机辅助评估。我们的方法区分手术能力跨越领域的术中表现。它推进了先前基于在非情境设置中使用当前手术模拟器的自动评估。我们的研究结果为未来使用SWBA方法对外科医生进行计算机辅助多领域能力评估提供了依据。
{"title":"Computer-assisted simulated workplace-based assessment in surgery: application of the universal framework of intraoperative performance within a mixed-reality simulation.","authors":"Philipp Stefan,&nbsp;Michael Pfandler,&nbsp;Aljoscha Kullmann,&nbsp;Ulrich Eck,&nbsp;Amelie Koch,&nbsp;Christoph Mehren,&nbsp;Anna von der Heide,&nbsp;Simon Weidert,&nbsp;Julian Fürmetz,&nbsp;Ekkehard Euler,&nbsp;Marc Lazarovici,&nbsp;Nassir Navab,&nbsp;Matthias Weigl","doi":"10.1136/bmjsit-2022-000135","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000135","url":null,"abstract":"<p><strong>Objectives: </strong>Workplace-based assessment (WBA) is a key requirement of competency-based medical education in postgraduate surgical education. Although simulated workplace-based assessment (SWBA) has been proposed to complement WBA, it is insufficiently adopted in surgical education. In particular, approaches to criterion-referenced and automated assessment of intraoperative surgical competency in contextualized SWBA settings are missing.Main objectives were (1) application of the universal framework of intraoperative performance and exemplary adaptation to spine surgery (vertebroplasty); (2) development of computer-assisted assessment based on criterion-referenced metrics; and (3) implementation in contextualized, team-based operating room (OR) simulation, and evaluation of validity.</p><p><strong>Design: </strong>Multistage development and assessment study: (1) expert-based definition of performance indicators based on framework's performance domains; (2) development of respective assessment metrics based on preoperative planning and intraoperative performance data; (3) implementation in mixed-reality OR simulation and assessment of surgeons operating in a confederate team. Statistical analyses included internal consistency and interdomain associations, correlations with experience, and technical and non-technical performances.</p><p><strong>Setting: </strong>Surgical simulation center. Full surgical team set-up within mixed-reality OR simulation.</p><p><strong>Participants: </strong>Eleven surgeons were recruited from two teaching hospitals. Eligibility criteria included surgical specialists in orthopedic, trauma, or neurosurgery with prior VP or kyphoplasty experience.</p><p><strong>Main outcome measures: </strong>Computer-assisted assessment of surgeons' intraoperative performance.</p><p><strong>Results: </strong>Performance scores were associated with surgeons' experience, observational assessment (Objective Structured Assessment of Technical Skill) scores and overall pass/fail ratings. Results provide strong evidence for validity of our computer-assisted SWBA approach. Diverse indicators of surgeons' technical and non-technical performances could be quantified and captured.</p><p><strong>Conclusions: </strong>This study is the first to investigate computer-assisted assessment based on a competency framework in authentic, contextualized team-based OR simulation. Our approach discriminates surgical competency across the domains of intraoperative performance. It advances previous automated assessment based on the use of current surgical simulators in decontextualized settings. Our findings inform future use of computer-assisted multidomain competency assessments of surgeons using SWBA approaches.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/be/bmjsit-2022-000135.PMC9853221.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10544506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathway map development for medical device event reporting in operating theatres: a human factors approach to improving the existing system. 手术室医疗器械事件报告的路径图开发:改进现有系统的人为因素方法。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000155
Arkeliana Tase, Massimo Micocci, Peter Buckle, Melody Ni, George Hanna

Objectives: This study aimed to develop the actual pathway to reporting and information transfer in operating theatres in relation to medical technology malfunction/failure. This with the aim of understanding the differences with the pathway published by NHS Improvement and identification of points for improvement.

Design: This is a qualitative study involving stakeholder interviews with doctors, nurses, manufacturers, medical device safety officer and Medicines and Healthcare products Regulatory Agency.

Setting: Data were collected on reporting pathway used in operating theatres. Clinical staff who took part worked in different trusts throughout UK while manufacturers provided devices in UK and EU/USA.

Participants: Semistructured interviews were completed with 15 clinicians and 13 manufacturers. Surveys were completed by 38 clinicians and 5 manufacturers. Recognised methods of pathway development were used. The Lean Six Sigma principles adapted to healthcare were used to develop suggestions for improvement.

Main outcome measures: To identify the differences between the set pathway to reporting and information transfer to what is occurring on a day-to-day basis as reported by staff. Identify points in the pathway where improvements could be applied.

Results: The developed pathway demonstrated great complexity of the current reporting system for medical devices. It identified numerous areas that give rise to problems and multiple biases in decision making. This highlighted the core issues leading to under-reporting and lack of knowledge on device performance and patient risk. Suggestions for improvement were deduced based on end user requirements and identified problems.

Conclusions: This study has provided a detailed understanding of the key problem areas that exist within the current reporting system for medical devices and technology. The developed pathway sets to address the key problems to improve reporting outcomes. The identification of pathway differences between 'work as done' and 'work as imagined' can lead to development of quality improvements that could be systematically applied.

目的:本研究旨在建立手术室医疗技术故障报告与信息传递的实际途径。这样做的目的是了解与NHS改进和改进点的识别所公布的途径的差异。设计:这是一项定性研究,涉及对医生、护士、制造商、医疗设备安全官员和药品和保健产品监管机构的利益相关者进行访谈。设置:收集手术室使用的报告路径数据。参与的临床工作人员在英国各地的不同信托机构工作,而制造商在英国和欧盟/美国提供设备。参与者:与15名临床医生和13名制造商完成半结构化访谈。调查由38名临床医生和5家制造商完成。使用公认的途径发展方法。适用于医疗保健的精益六西格玛原则被用于提出改进建议。主要结果衡量标准:确定工作人员报告的既定报告途径和信息传递与日常发生的情况之间的差异。确定路径中可以应用改进的点。结果:开发的路径显示了当前医疗器械报告系统的复杂性。它确定了在决策过程中产生问题和多重偏见的许多领域。这突出了导致设备性能和患者风险少报和缺乏知识的核心问题。根据最终用户的需求和发现的问题,提出了改进建议。结论:本研究详细了解了现行医疗器械和技术申报制度中存在的关键问题领域。制定的途径旨在解决改善报告结果的关键问题。识别“已完成的工作”和“想象中的工作”之间的路径差异可以导致可以系统应用的质量改进的发展。
{"title":"Pathway map development for medical device event reporting in operating theatres: a human factors approach to improving the existing system.","authors":"Arkeliana Tase,&nbsp;Massimo Micocci,&nbsp;Peter Buckle,&nbsp;Melody Ni,&nbsp;George Hanna","doi":"10.1136/bmjsit-2022-000155","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000155","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to develop the actual pathway to reporting and information transfer in operating theatres in relation to medical technology malfunction/failure. This with the aim of understanding the differences with the pathway published by NHS Improvement and identification of points for improvement.</p><p><strong>Design: </strong>This is a qualitative study involving stakeholder interviews with doctors, nurses, manufacturers, medical device safety officer and Medicines and Healthcare products Regulatory Agency.</p><p><strong>Setting: </strong>Data were collected on reporting pathway used in operating theatres. Clinical staff who took part worked in different trusts throughout UK while manufacturers provided devices in UK and EU/USA.</p><p><strong>Participants: </strong>Semistructured interviews were completed with 15 clinicians and 13 manufacturers. Surveys were completed by 38 clinicians and 5 manufacturers. Recognised methods of pathway development were used. The Lean Six Sigma principles adapted to healthcare were used to develop suggestions for improvement.</p><p><strong>Main outcome measures: </strong>To identify the differences between the set pathway to reporting and information transfer to what is occurring on a day-to-day basis as reported by staff. Identify points in the pathway where improvements could be applied.</p><p><strong>Results: </strong>The developed pathway demonstrated great complexity of the current reporting system for medical devices. It identified numerous areas that give rise to problems and multiple biases in decision making. This highlighted the core issues leading to under-reporting and lack of knowledge on device performance and patient risk. Suggestions for improvement were deduced based on end user requirements and identified problems.</p><p><strong>Conclusions: </strong>This study has provided a detailed understanding of the key problem areas that exist within the current reporting system for medical devices and technology. The developed pathway sets to address the key problems to improve reporting outcomes. The identification of pathway differences between 'work as done' and 'work as imagined' can lead to development of quality improvements that could be systematically applied.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/94/bmjsit-2022-000155.PMC9980347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10837173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Developing the foundation for assessment of devices used for Acute Ischemic Stroke Interventions (DAISI) using a Coordinated Registry Network. 更正:为使用协调注册网络评估用于急性缺血性卒中干预(DAISI)的设备奠定基础。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2021-000113corr1
[This corrects the article DOI: 10.1136/bmjsit-2021-000113.].
[这更正了文章DOI: 10.1136/bmjsit-2021-000113.]。
{"title":"Correction: Developing the foundation for assessment of devices used for Acute Ischemic Stroke Interventions (DAISI) using a Coordinated Registry Network.","authors":"","doi":"10.1136/bmjsit-2021-000113corr1","DOIUrl":"https://doi.org/10.1136/bmjsit-2021-000113corr1","url":null,"abstract":"[This corrects the article DOI: 10.1136/bmjsit-2021-000113.].","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/5b/bmjsit-2021-000113corr1.PMC10030792.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iterative evaluation of novel access techniques for small bowel obstruction: combining image guided, percutaneous, and endoscopic methods. 小肠梗阻新入路技术的迭代评估:结合图像引导、经皮和内镜方法。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000150
Kentaro Matsuo, Shinya Urakawa, Matthew Symer, Art Sedrakyan, Bradley Pua, Jeffrey Milsom

Objective: To avoid the need for extensive adhesiolysis in patients with small bowel obstruction (SBO). We evaluated the feasibility of using advanced imaging, percutaneous access, and endoscopy as alternative therapies for SBO.

Design: Retrospective case series (IDEAL [Idea, Development, Exploration, Assessment, and Long-term Study Collaborative] stages 1 and 2a).

Setting: Single tertiary referral center.

Participants: Twelve adults with chronic SBO resulting from inflammatory bowel disease, disseminated cancer, radiation, and/or adhesive disease. Participants were included if they underwent one of three novel access procedures. There were no exclusion criteria. The median age of participants was 67.5 years (range 42-81); two-thirds were women; and median American Society of Anesthesiology class was 3.

Interventions: All participants underwent one of three novel access methods, followed by wire-guided balloon dilation of a narrowed area of small bowel. These methods combined endoscopic, fluoroscopic, and surgical techniques. The techniques were (1) a purely endoscopic approach aided by an over-the-scope double-balloon device, (2) a combined endoscopic and percutaneous approach, and (3) a cut-down approach.

Main outcome measures: Procedural success (defined as successful access to the small bowel and successful balloon dilation of the stenotic area). Secondary outcomes included major complications, recurrence, length of stay, and procedure time.

Results: Procedural success was achieved in 10 of 12 patients (83%). At the time of median follow-up of 10 months, recurrence of SBO was observed in two patients. In only one patient, the novel method did not change the treatment plan. No major complications occurred. Conventional operative intervention was avoided in all patients who achieved technical success with one of the novel approaches. The median postprocedure length of hospital stay was 4 days. Median procedure time was 135 min.

Conclusions: Novel minimally invasive approaches to SBO represent feasible alternatives to surgical procedures in select patients. Further study should compare these approaches to standard ones as new methods are refined.

目的:避免小肠梗阻(SBO)患者进行广泛粘连松解术。我们评估了先进成像、经皮穿刺和内窥镜作为SBO替代疗法的可行性。设计:回顾性案例系列(IDEAL [Idea, Development, Exploration, Assessment, and Long-term Study Collaborative]阶段1和2a)。环境:单一三级转诊中心。参与者:12名由炎症性肠病、播散性癌症、放射和/或粘连性疾病引起的慢性SBO成人。如果参与者接受了三种新的访问程序中的一种,他们就被包括在内。没有排除标准。参与者的中位年龄为67.5岁(42-81岁);三分之二是女性;美国麻醉学学会的中位数为3。干预措施:所有的参与者都接受了三种新颖的进入方法中的一种,然后是钢丝引导的气球扩张狭窄的小肠区域。这些方法结合了内窥镜、透视和外科技术。这些技术包括:(1)在镜外双气囊装置辅助下的纯内窥镜入路,(2)内窥镜和经皮联合入路,以及(3)切口入路。主要观察指标:手术成功(定义为成功进入小肠和成功扩张狭窄区域)。次要结果包括主要并发症、复发、住院时间和手术时间。结果:12例患者中10例(83%)手术成功。中位随访10个月时,2例患者出现SBO复发。只有一个病人,新方法没有改变治疗计划。无重大并发症发生。所有采用新方法取得技术成功的患者均避免了常规手术干预。术后住院时间中位数为4天。中位手术时间为135分钟。结论:新型微创入路治疗SBO在特定患者中是外科手术的可行选择。随着新方法的完善,进一步的研究应该将这些方法与标准方法进行比较。
{"title":"Iterative evaluation of novel access techniques for small bowel obstruction: combining image guided, percutaneous, and endoscopic methods.","authors":"Kentaro Matsuo,&nbsp;Shinya Urakawa,&nbsp;Matthew Symer,&nbsp;Art Sedrakyan,&nbsp;Bradley Pua,&nbsp;Jeffrey Milsom","doi":"10.1136/bmjsit-2022-000150","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000150","url":null,"abstract":"<p><strong>Objective: </strong>To avoid the need for extensive adhesiolysis in patients with small bowel obstruction (SBO). We evaluated the feasibility of using advanced imaging, percutaneous access, and endoscopy as alternative therapies for SBO.</p><p><strong>Design: </strong>Retrospective case series (IDEAL [Idea, Development, Exploration, Assessment, and Long-term Study Collaborative] stages 1 and 2a).</p><p><strong>Setting: </strong>Single tertiary referral center.</p><p><strong>Participants: </strong>Twelve adults with chronic SBO resulting from inflammatory bowel disease, disseminated cancer, radiation, and/or adhesive disease. Participants were included if they underwent one of three novel access procedures. There were no exclusion criteria. The median age of participants was 67.5 years (range 42-81); two-thirds were women; and median American Society of Anesthesiology class was 3.</p><p><strong>Interventions: </strong>All participants underwent one of three novel access methods, followed by wire-guided balloon dilation of a narrowed area of small bowel. These methods combined endoscopic, fluoroscopic, and surgical techniques. The techniques were (1) a purely endoscopic approach aided by an over-the-scope double-balloon device, (2) a combined endoscopic and percutaneous approach, and (3) a cut-down approach.</p><p><strong>Main outcome measures: </strong>Procedural success (defined as successful access to the small bowel and successful balloon dilation of the stenotic area). Secondary outcomes included major complications, recurrence, length of stay, and procedure time.</p><p><strong>Results: </strong>Procedural success was achieved in 10 of 12 patients (83%). At the time of median follow-up of 10 months, recurrence of SBO was observed in two patients. In only one patient, the novel method did not change the treatment plan. No major complications occurred. Conventional operative intervention was avoided in all patients who achieved technical success with one of the novel approaches. The median postprocedure length of hospital stay was 4 days. Median procedure time was 135 min.</p><p><strong>Conclusions: </strong>Novel minimally invasive approaches to SBO represent feasible alternatives to surgical procedures in select patients. Further study should compare these approaches to standard ones as new methods are refined.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/91/bmjsit-2022-000150.PMC10201263.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9510058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safe implementation of surgical innovation: a prospective registry of the Versius Robotic Surgical System. 手术创新的安全实施:version机器人手术系统的前瞻性注册表。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000144
Ilias Soumpasis, Samer Nashef, Joel Dunning, Paul Moran, Mark Slack

Objectives: To describe a new, international, prospective surgical registry developed to accompany the clinical implementation of the Versius Robotic Surgical System by accumulating real-world evidence of its safety and effectiveness.

Interventions: This robotic surgical system was introduced in 2019 for its first live-human case. With its introduction, cumulative database enrollment was initiated across several surgical specialties, with systematic data collection via a secure online platform.

Main outcome measures: Pre-operative data include diagnosis, planned procedure(s), characteristics (age, sex, body mass index and disease status) and surgical history. Peri-operative data include operative time, intra-operative blood loss and use of blood transfusion products, intra-operative complications, conversion to an alternative technique, return to the operating room prior to discharge and length of hospital stay. Complications and mortality within 90 days of surgery are also recorded.

Results: The data collected in the registry are analyzed as comparative performance metrics, by meta-analyses or by individual surgeon performance using control method analysis. Continual monitoring of key performance indicators, using various types of analyses and outputs within the registry, have provided meaningful insights that help institutions, teams and individual surgeons to perform most effectively and ensure optimal patient safety.

Conclusions: Harnessing the power of large-scale, real-world registry data for routine surveillance of device performance in live-human surgery from first use will enhance the safety and efficacy outcomes of innovative surgical techniques. Data are crucial to driving the evolution of robot-assisted minimal access surgery while minimizing risk to patients.

Trial registration number: CTRI/2019/02/017872.

目的:通过积累其安全性和有效性的真实证据,描述一个新的、国际的、前瞻性的手术登记,以配合Versius机器人手术系统的临床实施。干预措施:该机器人手术系统于2019年推出,用于第一例活体手术。随着它的引入,通过安全的在线平台进行系统的数据收集,多个外科专业开始了累积数据库登记。主要观察指标:术前资料包括诊断、计划手术、特征(年龄、性别、体重指数和疾病状况)和手术史。围手术期数据包括手术时间、术中出血量和输血产品的使用、术中并发症、改用替代技术、出院前返回手术室和住院时间。同时记录手术90天内的并发症和死亡率。结果:在注册中心收集的数据被分析为比较绩效指标,通过荟萃分析或使用对照方法分析单个外科医生的绩效。通过对关键绩效指标的持续监测,在登记处使用各种类型的分析和输出,提供了有意义的见解,帮助机构、团队和外科医生个人最有效地执行任务,确保最佳的患者安全。结论:利用大规模、真实世界注册数据的力量,对活体手术中首次使用的器械性能进行常规监测,将提高创新手术技术的安全性和有效性。数据对于推动机器人辅助微创手术的发展至关重要,同时将患者的风险降至最低。试验注册号:CTRI/2019/02/017872。
{"title":"Safe implementation of surgical innovation: a prospective registry of the Versius Robotic Surgical System.","authors":"Ilias Soumpasis,&nbsp;Samer Nashef,&nbsp;Joel Dunning,&nbsp;Paul Moran,&nbsp;Mark Slack","doi":"10.1136/bmjsit-2022-000144","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000144","url":null,"abstract":"<p><strong>Objectives: </strong>To describe a new, international, prospective surgical registry developed to accompany the clinical implementation of the Versius Robotic Surgical System by accumulating real-world evidence of its safety and effectiveness.</p><p><strong>Interventions: </strong>This robotic surgical system was introduced in 2019 for its first live-human case. With its introduction, cumulative database enrollment was initiated across several surgical specialties, with systematic data collection via a secure online platform.</p><p><strong>Main outcome measures: </strong>Pre-operative data include diagnosis, planned procedure(s), characteristics (age, sex, body mass index and disease status) and surgical history. Peri-operative data include operative time, intra-operative blood loss and use of blood transfusion products, intra-operative complications, conversion to an alternative technique, return to the operating room prior to discharge and length of hospital stay. Complications and mortality within 90 days of surgery are also recorded.</p><p><strong>Results: </strong>The data collected in the registry are analyzed as comparative performance metrics, by meta-analyses or by individual surgeon performance using control method analysis. Continual monitoring of key performance indicators, using various types of analyses and outputs within the registry, have provided meaningful insights that help institutions, teams and individual surgeons to perform most effectively and ensure optimal patient safety.</p><p><strong>Conclusions: </strong>Harnessing the power of large-scale, real-world registry data for routine surveillance of device performance in live-human surgery from first use will enhance the safety and efficacy outcomes of innovative surgical techniques. Data are crucial to driving the evolution of robot-assisted minimal access surgery while minimizing risk to patients.</p><p><strong>Trial registration number: </strong>CTRI/2019/02/017872.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/91/bmjsit-2022-000144.PMC9972451.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9186113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Systematic review of preoperative n-3 fatty acids in major gastrointestinal surgery. 大胃肠手术术前n-3脂肪酸的系统评价。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000172
Jason George, Daniel White, Barbara Fielding, Michael Scott, Timothy Rockall, Martin Brunel Whyte

Objectives: Perioperative nutrition aims to replenish nutritional stores before surgery and reduce postoperative complications. 'Immunonutrition' (including omega-3 fatty acids) may modulate the immune system and attenuate the postoperative inflammatory response. Hitherto, immunonutrition has overwhelmingly been administered in the postoperative period-however, this may be too late to provide benefit.

Design: A systematic literature search using MEDLINE and EMBASE for randomized controlled trials (RCTs).

Setting: Perioperative major gastrointestinal surgery.

Participants: Patients undergoing major gastrointestinal surgery.

Interventions: Omega-3 fatty acid supplementation commenced in the preoperative period, with or without continuation into postoperative period.

Main outcome measures: The effect of preoperative omega-3 fatty acids on inflammatory response and clinical outcomes.

Results: 833 studies were identified. After applying inclusion and exclusion criteria, 12 RCTs, involving 1456 randomized patients, were included. Ten articles exclusively enrolled patients with cancer. Seven studies used a combination of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) as the intervention and five studies used EPA alone. Eight out of 12 studies continued preoperative nutritional support into the postoperative period.Of the nine studies reporting mortality, no difference was seen. Duration of hospitalisation ranged from 4.5 to 18 days with intervention and 3.5 to 23.5 days with control. Omega-3 fatty acids had no effect on postoperative C-reactive protein and the effect on cytokines (including tumor necrosis factor-α, interleukin (IL)-6 and IL-10) was inconsistent. Ten of the 12 studies had low risk of bias, with one study having moderate bias from allocation and blinding.

Conclusions: There is insufficient evidence to support routine preoperative omega-3 fatty acid supplementation for major gastrointestinal surgery, even when this is continued after surgery.

Prospero registration number: CRD42018108333.

目的:围手术期营养旨在术前补充营养储备,减少术后并发症。“免疫营养”(包括omega-3脂肪酸)可以调节免疫系统,减轻术后炎症反应。迄今为止,免疫营养绝大多数是在术后给予的,然而,这可能太晚了,无法提供益处。设计:使用MEDLINE和EMBASE进行随机对照试验(rct)的系统文献检索。背景:围手术期大胃肠手术。参与者:接受胃肠大手术的患者。干预措施:术前开始补充Omega-3脂肪酸,术后可继续或不继续补充。主要观察指标:术前ω -3脂肪酸对炎症反应和临床结果的影响。结果:共纳入833项研究。应用纳入和排除标准后,纳入12项随机对照试验,共1456例随机患者。10篇文章专门招募了癌症患者。七项研究使用EPA(二十碳五烯酸)和DHA(二十二碳六烯酸)的组合作为干预措施,五项研究单独使用EPA。12项研究中有8项将术前营养支持持续到术后。在报告死亡率的9项研究中,没有发现差异。干预组住院时间为4.5至18天,对照组为3.5至23.5天。Omega-3脂肪酸对术后c反应蛋白无影响,对细胞因子(包括肿瘤坏死因子-α、白细胞介素(IL)-6、IL-10)的影响不一致。12项研究中有10项具有低偏倚风险,1项研究在分配和盲法方面具有中度偏倚。结论:没有足够的证据支持大型胃肠手术术前常规补充omega-3脂肪酸,即使在手术后继续补充。普洛斯彼罗注册号:CRD42018108333。
{"title":"Systematic review of preoperative n-3 fatty acids in major gastrointestinal surgery.","authors":"Jason George,&nbsp;Daniel White,&nbsp;Barbara Fielding,&nbsp;Michael Scott,&nbsp;Timothy Rockall,&nbsp;Martin Brunel Whyte","doi":"10.1136/bmjsit-2022-000172","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000172","url":null,"abstract":"<p><strong>Objectives: </strong>Perioperative nutrition aims to replenish nutritional stores before surgery and reduce postoperative complications. 'Immunonutrition' (including omega-3 fatty acids) may modulate the immune system and attenuate the postoperative inflammatory response. Hitherto, immunonutrition has overwhelmingly been administered in the postoperative period-however, this may be too late to provide benefit.</p><p><strong>Design: </strong>A systematic literature search using MEDLINE and EMBASE for randomized controlled trials (RCTs).</p><p><strong>Setting: </strong>Perioperative major gastrointestinal surgery.</p><p><strong>Participants: </strong>Patients undergoing major gastrointestinal surgery.</p><p><strong>Interventions: </strong>Omega-3 fatty acid supplementation commenced in the preoperative period, with or without continuation into postoperative period.</p><p><strong>Main outcome measures: </strong>The effect of preoperative omega-3 fatty acids on inflammatory response and clinical outcomes.</p><p><strong>Results: </strong>833 studies were identified. After applying inclusion and exclusion criteria, 12 RCTs, involving 1456 randomized patients, were included. Ten articles exclusively enrolled patients with cancer. Seven studies used a combination of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) as the intervention and five studies used EPA alone. Eight out of 12 studies continued preoperative nutritional support into the postoperative period.Of the nine studies reporting mortality, no difference was seen. Duration of hospitalisation ranged from 4.5 to 18 days with intervention and 3.5 to 23.5 days with control. Omega-3 fatty acids had no effect on postoperative C-reactive protein and the effect on cytokines (including tumor necrosis factor-α, interleukin (IL)-6 and IL-10) was inconsistent. Ten of the 12 studies had low risk of bias, with one study having moderate bias from allocation and blinding.</p><p><strong>Conclusions: </strong>There is insufficient evidence to support routine preoperative omega-3 fatty acid supplementation for major gastrointestinal surgery, even when this is continued after surgery.</p><p><strong>Prospero registration number: </strong>CRD42018108333.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/3d/bmjsit-2022-000172.PMC10314636.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators. 探索独特的设备标识符的实现和使用的现实世界的证据:与NESTcc卫生系统网络合作者的混合方法研究。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000167
Sanket S Dhruva, Jennifer L Ridgeway, Joseph S Ross, Joseph P Drozda, Natalia A Wilson

Objectives: To examine the current state of unique device identifier (UDI) implementation, including barriers and facilitators, among eight health systems participating in a research network committed to real-world evidence (RWE) generation for medical devices.

Design: Mixed methods, including a structured survey and semistructured interviews.

Setting: Eight health systems participating in the National Evaluation System for health Technology research network within the USA.

Participants: Individuals identified as being involved in or knowledgeable about UDI implementation or medical device identification from supply chain, information technology and high-volume procedural area(s) in their health system.

Main outcomes measures: Interview topics were related to UDI implementation, including barriers and facilitators; UDI use; benefits of UDI adoption; and vision for UDI implementation. Data were analysed using directed content analysis, drawing on prior conceptual models of UDI implementation and the Exploration, Preparation, Implementation, Sustainment framework. A brief survey of health system characteristics and scope of UDI implementation was also conducted.

Results: Thirty-five individuals completed interviews. Three of eight health systems reported having implemented UDI. Themes identified about barriers and facilitators to UDI implementation included knowledge of the UDI and its benefits among decision-makers; organisational systems, culture and networks that support technology and workflow changes; and external factors such as policy mandates and technology. A final theme focused on the availability of UDIs for RWE; lack of availability significantly hindered RWE studies on medical devices.

Conclusions: UDI adoption within health systems requires knowledge of and impetus to achieve operational and clinical benefits. These are necessary to support UDI availability for medical device safety and effectiveness studies and RWE generation.

目的:研究参与致力于医疗器械真实世界证据(RWE)生成研究网络的八个卫生系统中唯一设备标识符(UDI)实施的现状,包括障碍和促进因素。设计:混合方法,包括结构化调查和半结构化访谈。环境:参与美国国家卫生技术研究网络评估系统的8个卫生系统。参与者:被确定参与或了解UDI实施或医疗器械识别的个人,来自其卫生系统中的供应链、信息技术和大批量程序领域。主要结果测量:访谈主题与UDI的实施有关,包括障碍和促进因素;UDI使用;采用UDI的好处;以及UDI实施的愿景。使用定向内容分析分析数据,借鉴UDI实施的先前概念模型和探索、准备、实施、维持框架。对卫生系统特点和UDI实施范围进行了简要调查。结果:35人完成访谈。8个卫生系统中有3个报告实施了全民统一免疫。确定的关于UDI实施的障碍和促进因素的主题包括决策者对UDI的了解及其益处;支持技术和工作流程变化的组织系统、文化和网络;以及政策指令和技术等外部因素。最后一个主题是RWE的udi可用性;缺乏可用性严重阻碍了RWE对医疗器械的研究。结论:在卫生系统内采用UDI需要了解并推动实现业务和临床效益。这些对于支持UDI用于医疗器械安全性和有效性研究以及RWE生成是必要的。
{"title":"Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators.","authors":"Sanket S Dhruva,&nbsp;Jennifer L Ridgeway,&nbsp;Joseph S Ross,&nbsp;Joseph P Drozda,&nbsp;Natalia A Wilson","doi":"10.1136/bmjsit-2022-000167","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000167","url":null,"abstract":"<p><strong>Objectives: </strong>To examine the current state of unique device identifier (UDI) implementation, including barriers and facilitators, among eight health systems participating in a research network committed to real-world evidence (RWE) generation for medical devices.</p><p><strong>Design: </strong>Mixed methods, including a structured survey and semistructured interviews.</p><p><strong>Setting: </strong>Eight health systems participating in the National Evaluation System for health Technology research network within the USA.</p><p><strong>Participants: </strong>Individuals identified as being involved in or knowledgeable about UDI implementation or medical device identification from supply chain, information technology and high-volume procedural area(s) in their health system.</p><p><strong>Main outcomes measures: </strong>Interview topics were related to UDI implementation, including barriers and facilitators; UDI use; benefits of UDI adoption; and vision for UDI implementation. Data were analysed using directed content analysis, drawing on prior conceptual models of UDI implementation and the Exploration, Preparation, Implementation, Sustainment framework. A brief survey of health system characteristics and scope of UDI implementation was also conducted.</p><p><strong>Results: </strong>Thirty-five individuals completed interviews. Three of eight health systems reported having implemented UDI. Themes identified about barriers and facilitators to UDI implementation included knowledge of the UDI and its benefits among decision-makers; organisational systems, culture and networks that support technology and workflow changes; and external factors such as policy mandates and technology. A final theme focused on the availability of UDIs for RWE; lack of availability significantly hindered RWE studies on medical devices.</p><p><strong>Conclusions: </strong>UDI adoption within health systems requires knowledge of and impetus to achieve operational and clinical benefits. These are necessary to support UDI availability for medical device safety and effectiveness studies and RWE generation.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/47/bmjsit-2022-000167.PMC9872505.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9177873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018. 2001年至2018年间获得FDA上市前批准的新型高风险治疗器械制造商之间的市场竞争。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000152
Vinay K Rathi, James L Johnston, Sanket Dhruva, Joseph Ross
© Author(s) (or their employer(s)) 2023. Reuse permitted under CC BYNC. No commercial reuse. See rights and permissions. Published by BMJ. INTRODUCTION The US Food and Drug Administration (FDA) regulates highrisk medical devices through the premarket approval (PMA) pathway, which requires clinical evidence assuring safety and effectiveness for approval. After approval, manufacturers may face barriers to successful commercialization, such as uncertainties about reimbursement or limited market exclusivity. 3 These clinical, financial and operational hurdles may discourage market entry by manufacturers, thereby limiting competitive innovation. We sought to evaluate the extent of market entry by manufacturers of firstinclass devices and subsequent competitors.
{"title":"Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018.","authors":"Vinay K Rathi,&nbsp;James L Johnston,&nbsp;Sanket Dhruva,&nbsp;Joseph Ross","doi":"10.1136/bmjsit-2022-000152","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000152","url":null,"abstract":"© Author(s) (or their employer(s)) 2023. Reuse permitted under CC BYNC. No commercial reuse. See rights and permissions. Published by BMJ. INTRODUCTION The US Food and Drug Administration (FDA) regulates highrisk medical devices through the premarket approval (PMA) pathway, which requires clinical evidence assuring safety and effectiveness for approval. After approval, manufacturers may face barriers to successful commercialization, such as uncertainties about reimbursement or limited market exclusivity. 3 These clinical, financial and operational hurdles may discourage market entry by manufacturers, thereby limiting competitive innovation. We sought to evaluate the extent of market entry by manufacturers of firstinclass devices and subsequent competitors.","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/ac/bmjsit-2022-000152.PMC9923248.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting total knee replacement at 2 and 5 years in osteoarthritis patients using machine learning. 使用机器学习预测骨关节炎患者2年和5年的全膝关节置换术。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000141
Khadija Mahmoud, M Abdulhadi Alagha, Zuzanna Nowinka, Gareth Jones

Objectives: Knee osteoarthritis is a major cause of physical disability and reduced quality of life, with end-stage disease often treated by total knee replacement (TKR). We set out to develop and externally validate a machine learning model capable of predicting the need for a TKR in 2 and 5 years time using routinely collected health data.

Design: A prospective study using datasets Osteoarthritis Initiative (OAI) and the Multicentre Osteoarthritis Study (MOST). OAI data were used to train the models while MOST data formed the external test set. The data were preprocessed using feature selection to curate 45 candidate features including demographics, medical history, imaging assessments, history of intervention and outcome.

Setting: The study was conducted using two multicentre USA-based datasets of participants with or at high risk of knee OA.

Participants: The study excluded participants with at least one existing TKR. OAI dataset included participants aged 45-79 years of which 3234 were used for training and 809 for internal testing, while MOST involved participants aged 50-79 and 2248 were used for external testing.

Main outcome measures: The primary outcome of this study was prediction of TKR onset at 2 and 5 years. Performance was evaluated using area under the curve (AUC) and F1-score and key predictors identified.

Results: For the best performing model (gradient boosting machine), the AUC at 2 years was 0.913 (95% CI 0.876 to 0.951), and at 5 years 0.873 (95% CI 0.839 to 0.907). Radiographic-derived features, questionnaire-based assessments alongside the patient's educational attainment were key predictors for these models.

Conclusions: Our approach suggests that routinely collected patient data are sufficient to drive a predictive model with a clinically acceptable level of accuracy (AUC>0.7) and is the first such tool to be externally validated. This level of accuracy is higher than previously published models utilising MRI data, which is not routinely collected.

目的:膝关节骨性关节炎是导致身体残疾和生活质量下降的主要原因,终末期疾病通常通过全膝关节置换术(TKR)治疗。我们着手开发并外部验证一种机器学习模型,该模型能够使用常规收集的健康数据预测2至5年内对TKR的需求。设计:一项使用骨关节炎倡议(OAI)和多中心骨关节炎研究(MOST)数据集的前瞻性研究。OAI数据用于训练模型,MOST数据构成外部测试集。使用特征选择对数据进行预处理,筛选出45个候选特征,包括人口统计学、病史、影像学评估、干预史和结果。背景:本研究采用美国的两个多中心数据集进行,参与者均为膝关节OA的高危人群。参与者:该研究排除了至少有一个现有TKR的参与者。OAI数据集包括45-79岁的参与者,其中3234人用于培训,809人用于内部测试,而大多数参与者年龄为50-79岁,2248人用于外部测试。主要结局指标:本研究的主要结局是预测2年和5年TKR发病情况。使用曲线下面积(AUC)和f1评分以及确定的关键预测因子来评估性能。结果:对于表现最好的模型(梯度增强机),2年的AUC为0.913 (95% CI 0.876 ~ 0.951), 5年的AUC为0.873 (95% CI 0.839 ~ 0.907)。放射学衍生的特征、基于问卷的评估以及患者的教育程度是这些模型的关键预测因素。结论:我们的方法表明,常规收集的患者数据足以驱动具有临床可接受精度水平(AUC>0.7)的预测模型,并且是第一个外部验证的此类工具。这一精度水平高于以前发表的利用MRI数据的模型,而MRI数据不是常规收集的。
{"title":"Predicting total knee replacement at 2 and 5 years in osteoarthritis patients using machine learning.","authors":"Khadija Mahmoud,&nbsp;M Abdulhadi Alagha,&nbsp;Zuzanna Nowinka,&nbsp;Gareth Jones","doi":"10.1136/bmjsit-2022-000141","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000141","url":null,"abstract":"<p><strong>Objectives: </strong>Knee osteoarthritis is a major cause of physical disability and reduced quality of life, with end-stage disease often treated by total knee replacement (TKR). We set out to develop and externally validate a machine learning model capable of predicting the need for a TKR in 2 and 5 years time using routinely collected health data.</p><p><strong>Design: </strong>A prospective study using datasets Osteoarthritis Initiative (OAI) and the Multicentre Osteoarthritis Study (MOST). OAI data were used to train the models while MOST data formed the external test set. The data were preprocessed using feature selection to curate 45 candidate features including demographics, medical history, imaging assessments, history of intervention and outcome.</p><p><strong>Setting: </strong>The study was conducted using two multicentre USA-based datasets of participants with or at high risk of knee OA.</p><p><strong>Participants: </strong>The study excluded participants with at least one existing TKR. OAI dataset included participants aged 45-79 years of which 3234 were used for training and 809 for internal testing, while MOST involved participants aged 50-79 and 2248 were used for external testing.</p><p><strong>Main outcome measures: </strong>The primary outcome of this study was prediction of TKR onset at 2 and 5 years. Performance was evaluated using area under the curve (AUC) and F1-score and key predictors identified.</p><p><strong>Results: </strong>For the best performing model (gradient boosting machine), the AUC at 2 years was 0.913 (95% CI 0.876 to 0.951), and at 5 years 0.873 (95% CI 0.839 to 0.907). Radiographic-derived features, questionnaire-based assessments alongside the patient's educational attainment were key predictors for these models.</p><p><strong>Conclusions: </strong>Our approach suggests that routinely collected patient data are sufficient to drive a predictive model with a clinically acceptable level of accuracy (AUC>0.7) and is the first such tool to be externally validated. This level of accuracy is higher than previously published models utilising MRI data, which is not routinely collected.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/4d/bmjsit-2022-000141.PMC9933661.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10772204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct phenotypes of kidney transplant recipients aged 80 years or older in the USA by machine learning consensus clustering. 通过机器学习共识聚类分析美国80岁或以上肾移植受者的不同表型。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1136/bmjsit-2022-000137
Charat Thongprayoon, Caroline C Jadlowiec, Shennen A Mao, Michael A Mao, Napat Leeaphorn, Wisit Kaewput, Pattharawin Pattharanitima, Pitchaphon Nissaisorakarn, Matthew Cooper, Wisit Cheungpasitporn

Objectives: This study aimed to identify distinct clusters of very elderly kidney transplant recipients aged ≥80 and assess clinical outcomes among these unique clusters.

Design: Cohort study with machine learning (ML) consensus clustering approach.

Setting and participants: All very elderly (age ≥80 at time of transplant) kidney transplant recipients in the Organ Procurement and Transplantation Network/United Network for Organ Sharing database database from 2010 to 2019.

Main outcome measures: Distinct clusters of very elderly kidney transplant recipients and their post-transplant outcomes including death-censored graft failure, overall mortality and acute allograft rejection among the assigned clusters.

Results: Consensus cluster analysis was performed in 419 very elderly kidney transplant and identified three distinct clusters that best represented the clinical characteristics of very elderly kidney transplant recipients. Recipients in cluster 1 received standard Kidney Donor Profile Index (KDPI) non-extended criteria donor (ECD) kidneys from deceased donors. Recipients in cluster 2 received kidneys from older, hypertensive ECD deceased donors with a KDPI score ≥85%. Kidneys for cluster 2 patients had longer cold ischaemia time and the highest use of machine perfusion. Recipients in clusters 1 and 2 were more likely to be on dialysis at the time of transplant (88.3%, 89.4%). Recipients in cluster 3 were more likely to be preemptive (39%) or had a dialysis duration less than 1 year (24%). These recipients received living donor kidney transplants. Cluster 3 had the most favourable post-transplant outcomes. Compared with cluster 3, cluster 1 had comparable survival but higher death-censored graft failure, while cluster 2 had lower patient survival, higher death-censored graft failure and more acute rejection.

Conclusions: Our study used an unsupervised ML approach to cluster very elderly kidney transplant recipients into three clinically unique clusters with distinct post-transplant outcomes. These findings from an ML clustering approach provide additional understanding towards individualised medicine and opportunities to improve care for very elderly kidney transplant recipients.

目的:本研究旨在确定≥80岁高龄肾移植受者的不同群体,并评估这些独特群体的临床结果。设计:采用机器学习(ML)共识聚类方法的队列研究。环境和参与者:2010年至2019年器官获取和移植网络/器官共享联合网络数据库数据库中的所有高龄(移植时年龄≥80岁)肾移植受者。主要结果测量:特高龄肾移植受者的不同群体及其移植后的结果,包括死亡审查的移植物衰竭、总死亡率和指定群体中的急性同种异体移植排斥反应。结果:对419例高龄肾移植患者进行了一致聚类分析,确定了最能代表高龄肾移植受者临床特征的三个不同的聚类。第1组的受赠者接受了已故供者的标准肾供者档案指数(KDPI)非扩展标准供者(ECD)肾脏。第2组接受的肾脏来自KDPI评分≥85%的老年高血压ECD死亡供者。第2组患者的肾脏冷缺血时间较长,机器灌注的使用率最高。第1组和第2组的受者更有可能在移植时进行透析(88.3%,89.4%)。第3组的受者更有可能是先发制人的(39%)或透析持续时间少于1年(24%)。这些接受者接受了活体肾脏移植。第3组移植后预后最好。与第3类相比,第1类患者的生存期相当,但死亡审查的移植物衰竭发生率较高,而第2类患者的生存期较低,死亡审查的移植物衰竭发生率较高,急性排斥反应发生率较高。结论:我们的研究使用无监督ML方法将高龄肾移植受者分为三个临床独特的组,这些组具有不同的移植后预后。这些来自ML聚类方法的发现为个性化医疗提供了额外的理解,并为改善高龄肾移植受者的护理提供了机会。
{"title":"Distinct phenotypes of kidney transplant recipients aged 80 years or older in the USA by machine learning consensus clustering.","authors":"Charat Thongprayoon,&nbsp;Caroline C Jadlowiec,&nbsp;Shennen A Mao,&nbsp;Michael A Mao,&nbsp;Napat Leeaphorn,&nbsp;Wisit Kaewput,&nbsp;Pattharawin Pattharanitima,&nbsp;Pitchaphon Nissaisorakarn,&nbsp;Matthew Cooper,&nbsp;Wisit Cheungpasitporn","doi":"10.1136/bmjsit-2022-000137","DOIUrl":"https://doi.org/10.1136/bmjsit-2022-000137","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to identify distinct clusters of very elderly kidney transplant recipients aged ≥80 and assess clinical outcomes among these unique clusters.</p><p><strong>Design: </strong>Cohort study with machine learning (ML) consensus clustering approach.</p><p><strong>Setting and participants: </strong>All very elderly (age ≥80 at time of transplant) kidney transplant recipients in the Organ Procurement and Transplantation Network/United Network for Organ Sharing database database from 2010 to 2019.</p><p><strong>Main outcome measures: </strong>Distinct clusters of very elderly kidney transplant recipients and their post-transplant outcomes including death-censored graft failure, overall mortality and acute allograft rejection among the assigned clusters.</p><p><strong>Results: </strong>Consensus cluster analysis was performed in 419 very elderly kidney transplant and identified three distinct clusters that best represented the clinical characteristics of very elderly kidney transplant recipients. Recipients in cluster 1 received standard Kidney Donor Profile Index (KDPI) non-extended criteria donor (ECD) kidneys from deceased donors. Recipients in cluster 2 received kidneys from older, hypertensive ECD deceased donors with a KDPI score ≥85%. Kidneys for cluster 2 patients had longer cold ischaemia time and the highest use of machine perfusion. Recipients in clusters 1 and 2 were more likely to be on dialysis at the time of transplant (88.3%, 89.4%). Recipients in cluster 3 were more likely to be preemptive (39%) or had a dialysis duration less than 1 year (24%). These recipients received living donor kidney transplants. Cluster 3 had the most favourable post-transplant outcomes. Compared with cluster 3, cluster 1 had comparable survival but higher death-censored graft failure, while cluster 2 had lower patient survival, higher death-censored graft failure and more acute rejection.</p><p><strong>Conclusions: </strong>Our study used an unsupervised ML approach to cluster very elderly kidney transplant recipients into three clinically unique clusters with distinct post-transplant outcomes. These findings from an ML clustering approach provide additional understanding towards individualised medicine and opportunities to improve care for very elderly kidney transplant recipients.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/b1/bmjsit-2022-000137.PMC9944353.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10792650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
BMJ Surgery Interventions Health Technologies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1